EPO

New study examines the validity of epo testing

BETHESDA, Md. (June 26, 2008)Recombinant human erythropoietin (rHuEpo) is a genetically engineered hormone sometimes misused by high-performance athletes such as cyclists and marathon runners to boost their endurance. The potential misuse of the drug is detected in urine collected from athletes. S...

Progress toward an alternative for EPO: Gas6 offers remedy where EPO fails today

Leuven, Belgium − Many patients with a chronic disease or cancer have to contend with anemia − and the severe fatigue that accompanies anemia impedes the patient considerably in his or her daily activities. At present, the hormone EPO is administered to a large number of these patients...

Dragon Sells EPO Business; Focus on Antibiotic Core Business

VANCOUVER, Nov. 14 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. (TSX: DDD; OTCBB: DRUG; BBSE: DRP) today announced that it has entered an agreement with an unaffiliated party for the sale of its EPO business which accounted for less than 3% of Dragon's consolidated revenue for the first...

Independent Health to Begin Offering Its Members Vitamins, Supplements and Natural Products

... for customer service and member satisfaction. Independent Health's comprehensive portfolio of product and service offerings include HMO, POS, PPO and epo products, Medicare and Medicaid plans, traditional indemnity insurance, consumer-directed plans, coverage for self-funded employers, plus health savin...

GPhA Statement on FTC Report on 'Follow-on Biologic Drug Competition'

...hem. And they are also placing an enormous financial burden on our federal government. The federal government through Medicare Part B spent more for epo in 2007 than FDA had for its entire FY2008 budget. As the FTC report clearly states, biogenerics 'if brought to market, could reduce the estimated $40...

Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa

...ulative ESA cost was $4,321 for patients receiving epo vs. $6,089 for DARB patients ( p <0.0001). The dose ratio was 255 units of epo to 1 microgram (mcg) of DARB. The authors stated ...ten is used to compare the relative utilization of epo and DARB because...

Top U.S. Professional Cycling Team, Garmin-Slipstream, Partners With ADSI to Continue Anti-Doping Program

... 29 athletes on the team are voluntarily participating in the program, which will test them over 600 times in 2009. There will be an intense focus on epo and related substances as well as continued focus on longitudinal profiling of blood and steroid levels. Detection of traditional doping products wil...

Late-breaking data to be presented at the American Society of Hematology Annual Meeting

...ickle cell disease. Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the epo IPD Meta-Analysis Collaborative Group [LBA-6] Julia Bohlius, MD, MScPH, University of Bern, Bern, Switzerland *Abstract LBA-6 is being presented ...

Lakeside Systems, Inc. Unifies Integrated Healthcare Delivery System under New Brand: Lakeside Community Healthcare

...heir primary care physicians. Lakeside Community Healthcare physicians and ancillary services accept a full range of health plans, including HMO, PPO, epo and other offerings. Lakeside was just named by the San Fernando Valley Business Journal as the number one fastest growing private company in its re...

Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More

... of the existing tests. They've shown that if you don't do the test soon after people take the drug, it may be very difficult to detect (especially if epo is take in low doses)," Dr. Joyner says. The Bottom Line: Keep Moving "Remember, while it's fun to watch sports and while we will all be tempted t...

More>>

EPO in Medical Technology

Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients

...his period. One of the patients received his last epo injection more than 200 days ago. This is contras...the FDA approved standard regimen of thrice weekly epo injections, in which typical patients would expect...igned to produce and deliver a therapeutic dose of epo steadily for up to six months or more, EPODURE Bio...

XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma

...ting their proliferation and differentiation and maintaining their viability. Over the last decade, several reports have indicated that the action of epo is not restricted to the erythroid compartment, but may have additional biological, and consequently potential therapeutic properties, broadly beyond ...

Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease

...target range for four months without receiving any epo injections. By contrast, in standard practice today, epo injections are required up to several times per we...our months while alleviating the need for frequent epo injections. The Phase I/II clinical trial wa...

Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting

...alyses were performed using data through Week 44. The mean baseline estimated glomerular filtration rate was 30 mL/min/1.73 m2 and the median weekly epo doses (IU) were 4,382, 4,364 and 6,091 for TIW, QW and Q2W groups, respectively. For the TIW, QW and Q2W groups, the mean baseline Hb was 9.6, 9.7 and...

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

...ntrast to the improvement in fatigue of anemic cancer patients treated with epo which occurred only when anemia was also improved, Soliris-treated PNH pati...bin level increased as compared to anemic cancer patients treated with epo who experienced only a small improvement in fatigue (ES: +0.48). * ...

Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings

...t National Managed Care Database to examine recent epo and DARB treatment patterns and corresponding ...s in newly-initiated CKD patients treated with epo (n=1,110) or DARB (n=723) not receiving dialys...is chronic kidney disease population receiving epo (n=1,066) or DARB (n=375) through a pharmacy b...

Roche responds to announcement of 'IDEAL' hepatitis C trial results

... is often given to treat ribavirin-related anemia and help patients maintain a higher ribavirin dose. However, physicians could only prescribe epo after the first dose ribavirin reduction in the "IDEAL" trial. Since patients in the Peg- Intron arms generally had smaller ribavirin dose red...

Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs

... peptide (CTP) technology significantly increased the half-life of standard epo in animal models.(1) The study, which assessed an early version of EPO-CTP,...s effective in raising hematocrit levels as the same total dose of standard epo administered in three injections over the course of a week. The current ve...

Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients

...iting the upper threshold of hemoglobin levels to 11. Additionally, the FDA made it clear that the label instructions were never intended to result in epo doses being withheld if a patient's hemoglobin level exceeded 12. Further, the committee stressed the need for small incremental dose adjustments of E...

Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)

...ician selected regimens: best supportive care alone, low-dose cytarabine plus best supportive care or standard chemotherapy plus best supportive care. epo and prophylactic G-CSF use was not permitted. The CCR represented standard of care within the territories where the trial was conducted. The study eva...

More>>

EPO in Biological Technology

3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results

...thropoietin ("EPO") products, continued to outpace epo market growth in China. Net revenue from EP...s market leadership position, with 41.1% of epo market share according to fourth quarter 2008 IMS ... sponsored by Amgen. The study shows that among 12 epo products manufactured in Asia, 3SBio's EPIA...

BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...his market may come from the proposed bundling structure under which Nephrologists project shifts to subcutaneous dosing, less aggressive treatment of epo hypo-responders, and increased focus on patients' iron status. The commercialization of new ESAs could also alter market dynamics in which Amgen's Ep...

Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia

...ve number needed to provide the intended low daily epo dose of 18-25 IU/kg/day in each subject. The hemog...which is thought to have curtailed the duration of epo delivery in the Company's previous Phase I Clinica...igned to produce and deliver a therapeutic dose of epo steadily for three to six months or more, in Augus...

GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology

...echnology has allowed GenOdyssee to identify in the population a variety of innovative variations on existing key protein drugs such as IFN alphas and epo and to convert such variations into novel drug candidates. The company's lead virology and immunotherapy drug candidates are GEA007.1 and GEA009.2, re...

3SBio Inc. Announces First Quarter 2008 Results

... market as well as from the strong underlying demand in the dialysis market; trends which we believe demonstrate the fundamental health of the Chinese epo market. Net revenues from our TPIAO product increased by 103.8% over the first quarter 2007 to RMB15.4 million (US$2.2 million) due to the continued i...

Japan Patent Office Licenses GeneCards(R) from Xennex, Inc.

...ol for professionals dealing with intellectual property in the life sciences area, including biotech, pharma, and intellectual property law firms. The epo has been using GeneCards very successfully for several years now; with the JPO's licensing of GeneCards, we continue to expand our presence in the int...

Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial

... active compound being developed to treat different types of anemia, such as CIA. PBI-1402 has a distinct mechanism of action and does not act through epo receptor. ProMetic has recently expanded its clinical program for PBI-1402 into the treatment of anemia in patients with myelodysplastic syndrome ("MD...

Dragon Pharma announces 2007 full year financial results

... per share, compared to an income of $5.4 million or $0.08 per share in 2006. 2007 Full Year Operational Highlights: - Dragon sold its epo business to fully focus on its core antibiotic business that has showed significant growth in the past few years. - Under the favorable market...

Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications

... is a major accomplishment and a step forward," she added. As part of the epo procedure, within a nine-month period following the date of granting of the...ing the patent, amending it or, in certain cases, revoking it. According to epo regulations, the opposed patent is considered and remains granted and enfor...

ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia

... active compound being developed to treat different types of anemia, such as CIA. PBI-1402 has a distinct mechanism of action and does not act through epo receptor. ProMetic has recently expanded its clinical program for PBI-1402 into the treatment of anemia in patients with myelodysplastic syndrome ("MD...

More>>

EPO in Biological Definition

Hormone

...l-natriuretic peptide (ANP, also atriopeptin) calcitonin cholecystokinin (CCK) corticotropin-releasing hormone (CRH) erythropoietin ( epo ) follicle stimulating hormone (FSH) gastrin glucagon gonadotropin-releasing hormone (GnRH) growth hormone-releasing hormone (GHRH...

EPO in Biological Dictionary

Exogenous DNA

... it is susceptible to ... The exogenous DNA is stably integrated into the cell genome or is expressed in ... The exogenous DNA encoding epo is introduced into cells operatively linked with ... ... and the available techniques to introduce exogenous DNA into yeast cells has ... t...